| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 12 |
| Referral date | 01 April 2005 |
| Topic area |
|
Provisional Schedule
| Consultation on draft scope by stakeholders: | October 2006 | |
| Closing date for invited submissions / evidence submission: | 10 May 2007 | |
| Final scope published: | January 2007 | |
| 1st appraisal committee meeting: | 03 October 2007 | |
| 2nd appraisal committee meeting: | 05 February 2008 | |
| 3rd appraisal committee meeting: | 03 April 2008 |
Project Team
| Assessment Group / Evidence Review Group: | West Midlands Health Technology Assessment Collaboration |
| Communications manager: | Kristin O'Leary |
| Executive Lead: | Peter Littlejohns |
| Project manager: | Jeremy Powell |
| Technical Lead: | Helen Knight |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 May 2005 | Topic summary published. |
| 17 October 2007 | Timelines extended to accommodate additional analysis requested by the committee. Second committee meeting rescheduled. |
| 09 November 2007 | Request to stakeholders seeking additional observational or registry data on the survival benefit provided by the drugs that are subject to this appraisal. |
| 28 October 2008 | Consultees and commentators were invited to comment on a revised remit, scope and provisional matrix |
| 25 November 2008 | Closing date for comment on draft scope, remit and matrix |
| 30 March 2009 | The appraisal was removed from the NICE work programme |
For further information on our processes and methods, please see our CHTE processes and methods manual